Larimar Therapeutics (LRMR) Net Shares Issued and Repurchased (2015 - 2025)

Larimar Therapeutics (LRMR) has reported Net Shares Issued and Repurchased for 11 consecutive years, with $2.4 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Net Shares Issued and Repurchased rose 9.03% year-over-year to $2.4 million; the trailing twelve-month figure through Dec 2025 stood at $2.4 million (up 9.03% YoY), and the FY2025 full-year result was $2.4 million, up 9.03% from the prior year.
• Net Shares Issued and Repurchased improved to $2.4 million in Q4 2025 per LRMR's latest filing, from $2.1 million in the prior quarter.
• Across five years, Net Shares Issued and Repurchased topped out at $2.4 million in Q4 2025 and bottomed at $402550.0 in Q1 2021.
• Historically, Net Shares Issued and Repurchased has averaged $1.4 million across 5 years, with a median of $1.4 million in 2023.
• The sharpest annual moves came in 2021 and 2023: Net Shares Issued and Repurchased slumped 53.78% in 2021, then jumped 114.33% in 2023.
• Over 5 years, Net Shares Issued and Repurchased stood at $626750.0 in 2021, then jumped by 40.16% to $878450.0 in 2022, then surged by 99.01% to $1.7 million in 2023, then advanced by 27.87% to $2.2 million in 2024, then advanced by 9.03% to $2.4 million in 2025.
• According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $2.4 million, $2.1 million, and $2.2 million for Q4 2025, Q1 2025, and Q4 2024 respectively.